Cargando…

Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs

BACKGROUND AND OBJECTIVE: The first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have shown significant therapeutic effects on patients harboring sensitive EGFR mutations, while the mechanisms related to drug resistance have still remained elusive. This study ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hai, Yang, Xiaohua, Hu, Fang, Li, Changhui, Xu, Jianlin, Nie, Wei, Shen, Yinchen, Lou, Yuqing, Han, Baohui, Zhong, Hua, Zhang, Xueyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295535/ https://www.ncbi.nlm.nih.gov/pubmed/32606756 http://dx.doi.org/10.2147/OTT.S250024

Ejemplares similares

Clinicopathological characteristics with EGFR, ALK, ROS1 genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma
por: Shen, Yinchen, et al.
Publicado: (2019)

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy
por: Shen, Yinchen, et al.
Publicado: (2020)

Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns
por: Hu, Fang, et al.
Publicado: (2019)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
por: Li, Changhui, et al.
Publicado: (2021)

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527
por: Li, Changhui, et al.
Publicado: (2021)

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
por: Xu, Jianlin, et al.
Publicado: (2016)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion
por: Zhang, Hai, et al.
Publicado: (2020)

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
por: Xu, Jianlin, et al.
Publicado: (2016)

Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
por: Lou, Yuqing, et al.
Publicado: (2021)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
por: Sun, Dantong, et al.
Publicado: (2020)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
por: Li, Changhui, et al.
Publicado: (2019)

Third generation EGFR TKIs: current data and future directions
por: Tan, Chee-Seng, et al.
Publicado: (2018)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
por: Chang, Chia-Hao, et al.
Publicado: (2020)

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
por: Zheng, Liang, et al.
Publicado: (2023)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

Wnt blockers inhibit the proliferation of lung cancer stem cells
por: Zhang, Xueyan, et al.
Publicado: (2015)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
por: Chu, Tianqing, et al.
Publicado: (2022)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
por: Takeda, Masayuki, et al.
Publicado: (2019)

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report
por: Chen, Yongxing, et al.
Publicado: (2020)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
por: Deng, Qinfang, et al.
Publicado: (2018)

Propensity score analysis of overall survival between first‐ and second‐generation EGFR‐TKIs using real‐world data
por: Ito, Kentaro, et al.
Publicado: (2020)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
por: Wu, Xuan, et al.
Publicado: (2013)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report
por: Zhang, Yan, et al.
Publicado: (2019)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kusfuj895qqs0mcpoqneoos90r